Scott Isaacs/LinkedIn
Sep 29, 2026, 16:27
Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
Scott Isaacs, Former President of American Association of Clinical Endocrinology (AACE), shared a post on LinkedIn:
“Decreased inflammation from GLP1 RAs leads to more stable plaques, myocardial remodeling, reduced cytokine storm, stronger gut barrier, and decreased immune hyperactivity in the brain and autoimmune disease.”
Title: Anti-inflammatory effects of GLP1-RA drugs
Authors: Luis Quintana, Nadim Tabaza, Berkan Kurt, Florian Kahles

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines